PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Status:
Recruiting
Trial end date:
2023-01-16
Target enrollment:
Participant gender:
Summary
Background:
About 5 million adults in the U.S. have Alzheimer s disease or another adult-onset
neurodegenerative disorder. Many studies have found that inflammation in the brain
contributes to these diseases. Researchers want to find a better way to measure this
inflammation.
Objective:
To learn whether COX-1 and/or COX-2 is elevated in the brains of individuals with
neurodegenerative brain disease compared to healthy volunteers.
Eligibility:
Adults age 18 years and older in good general health who have an adult-onset
neurodegenerative dementia, such as AD, FTD, corticobasal syndrome, or Huntington s disease
and healthy adult volunteers enrolled in protocols 01-M-0254 or 17-M-0181.
Design:
Participants will be screened with medical history, physical exam with vital signs, and lab
tests. They will have a neuropsychological testing. Their heart function will be measured.
Participants will have a magnetic resonance imaging (MRI) scan. The MRI scanner is a metal
tube surrounded by a strong magnetic field. Participants will lie on a table that slides in
and out of the tube. The machine makes noise. Participants will get earplugs.
Participants will have 2 PET scans. They will be injected with the study drugs through an
intravenous catheter placed in an arm vein. The PET scanner is shaped like a doughnut.
Participants will lie on a bed that slides in and out of the scanner. A plastic mask will be
molded to their head to keep them from moving. A thin plastic tube will be put into an artery
at the wrist or elbow crease area. This will be used to draw blood during the scan.
Participants will have 2-3 study visits. Participation lasts 1 week to 4 months, depending on
scheduling.